333: An H5N1 bird flu update and talent scarcity in the radiopharma field
Dec 5, 2024
auto_awesome
Helen Branswell, STAT’s infectious disease reporter, gives an urgent update on the ongoing H5N1 bird flu outbreak, highlighting a concerning rise in human cases and potential mutation risks. The discussion also covers key findings from a recent weight loss medication showdown between Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. Additionally, there's a deep dive into the talent shortage in the radiopharmaceutical industry, detailing the struggle to attract skilled professionals and the impact on cancer treatment innovations.
The rising number of H5N1 bird flu cases raises concerns about potential mutations allowing easier human transmission, alarming infectious disease experts.
The radiopharmaceutical industry is experiencing a talent scarcity, hindering advancements in cancer treatments as companies struggle to find skilled professionals like those in Europe.
Deep dives
Rising Concerns Over Bird Flu Outbreak
The ongoing H5N1 bird flu outbreak is becoming increasingly concerning, with the number of reported human cases rising to 59 across several states. While most of these cases have not been severe, there remains uncertainty about how infections are occurring, particularly highlighted by a teenager in Canada who has been hospitalized in serious condition after catching a variant of the virus. Scientists are puzzled by the relatively lower mortality rate in humans compared to the virus's high lethality in other mammals. This situation raises alarms among infectious disease experts who fear the virus could mutate to enable easier transmission between humans, particularly due to the involvement of pigs as potential mixing vessels for different virus strains.
Innovations in Obesity Treatments
Recent studies in obesity treatments are marking significant advancements, notably Eli Lilly's head-to-head trial comparing their drug ZepBound with Novo's Wagovi. The results indicated that ZepBound demonstrated superior weight loss, with patients losing approximately 20% of their body weight compared to about 13-14% for those taking Wagovi after a lengthy treatment period. These findings could provide Eli Lilly with a marketing edge, particularly if the data can be incorporated into ZepBound's prescription label. Additionally, Amgen's obesity drug candidate, Maritide, has showed promise with a favorable side effect profile and the potential for less frequent dosing, making it a competitive option in the obesity treatment landscape.
Talent Shortage in Radiopharmaceuticals
The field of radiopharmaceuticals is facing a talent shortage as demand for specialized knowledge in cancer therapies using radioactive materials surges. Many companies are struggling to find skilled professionals who understand the complexities of working with nuclear medicines, especially as the industry shifts towards new isotopes like actinium. Due to a lack of training programs in the U.S. compared to Europe, biotech firms are frequently unable to find candidates with the necessary expertise, leading to a competitive job market. Companies are now attempting to attract talent with high salaries and bonuses, as well as adjusting job requirements due to the reality of the limited pool of qualified applicants.
You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than eight months ago. Well, bird flu is still here and the number of reported cases in people is growing. STAT’s infectious disease reporter Helen Branswell joins us for an update. But first, we break down the results from a GLP-1 showdown study that compared Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy. Allison shares her recent reporting on a talent shortage that is posing new challenges to the fast-growing radiopharmaceutical industry.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode